...
首页> 外文期刊>Diabetes therapy >Accuracy Evaluation of CONTOUR?PLUS Compared With Four Blood Glucose Monitoring Systems
【24h】

Accuracy Evaluation of CONTOUR?PLUS Compared With Four Blood Glucose Monitoring Systems

机译:与四个血糖监测系统相比,CONTOUR?PLUS的准确性评估

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The aim of this study was to compare the accuracy of 5 blood glucose monitoring systems (BGMSs; CONTOUR?PLUS [CP], Accu-Chek? Active [ACA], Accu-Chek? Performa [ACP], FreeStyle Freedom? [FF], OneTouch? SelectSimple? [OTSS]). Methods: Study staff tested fingerstick samples from 106 subjects aged ≥18 years using the 5 BGMSs. Some samples were modified to achieve blood glucose concentrations throughout the measuring range. The primary endpoint was comparison of the mean absolute relative difference (MARD) from the reference value (Yellow Springs Instruments [YSI]) across the overall tested glucose range. Other endpoints were MARD in the low (≤80 mg/dL [≤4.4 mmol/L]), middle (81–180 mg/dL [4.5–10.0 mmol/L]), and high (>180 mg/dL [>10.0 mmol/L]) glucose ranges, and MARD for unmodified samples in the overall glucose range. Results: CONTOUR?PLUS had a statistically significantly lower MARD than all BGMSs across the overall tested range (27–460 mg/dL [1.5–25.5 mmol/L]) and in the high glucose range. In the low glucose range, CP had a lower MARD than all BGMSs, which was statistically significant except for ACP. For unmodified samples across the overall tested range, CP had a lower MARD than all BGMSs and was statistically significantly lower except for ACA. Conclusions: CONTOUR?PLUS had the lowest mean difference from the reference values (by MARD) when compared with other BGMSs across multiple glucose ranges with modified and unmodified samples. Funding: Bayer HealthCare LLC, Diabetes Care. Trial registration number: ClinicalTrials.gov Identifier NCT01714232.
机译:简介:本研究的目的是比较5种血糖监测系统(BGMS; CONTOUR?PLUS [CP],Accu-Chek?Active [ACA],Accu-Chek?Performa [ACP],FreeStyle Freedom?[ FF],OneTouch?SelectSimple?[OTSS])。方法:研究人员使用5个BGMS对来自年龄≥18岁的106名受试者的指尖样本进行了测试。修改了一些样品以在整个测量范围内达到血糖浓度。主要终点是在整个测试的葡萄糖范围内与参考值(Yellow Springs Instruments [YSI])的平均绝对相对差(MARD)进行比较。其他终点为低(≤80mg / dL [≤4.4mmol / L],中(81-180 mg / dL [4.5-10.0 mmol / L])和高(> 180 mg / dL [> 10.0 mmol / L])葡萄糖范围,未修饰样品的MARD在整个葡萄糖范围内。结果:在整个测试范围(27–460 mg / dL [1.5–25.5 mmol / L])和高血糖范围内,CONTOUR?PLUS的MARD均显着低于所有BGMS。在低血糖范围内,CP的MARD低于所有BGMS,除了ACP以外,在统计学上均具有统计学意义。对于整个测试范围内的未修饰样品,CP的MARD低于所有BGMS,并且统计学上显着低于ACA。结论:与其他BGMS相比,在修饰和未修饰样品的多个葡萄糖范围内,CONTOUR?PLUS与参考值(按MARD)的均值差异最低。资金来源:拜耳医药保健有限责任公司,糖尿病护理。试验注册号:ClinicalTrials.gov标识符NCT01714232。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号